21156 WEBCAST: The Multiple Myeloma Workshop: Exploring the Convergence of Novel Therapeutic Platforms, Cell Therapy and ASCT
In this new multiple myeloma (MM) CME program, two leading myeloma experts discuss key questions and controversies arising from the rapid validation of novel therapeutics for patients with MM who are autologous stem cell transplantation (ASCT) eligible. Although the use of ASCT remains a core therapeutic modality for MM, using ASCT in conjunction with innovative treatment options—including CAR-T cell therapy, proteasome inhibitors, immunomodulators, and antibodies such as, CD38 antibodies, BCMA-targeting antibody-drug conjugates, and bispecific antibodies—can substantially improve outcomes. These improvements have been observed across the continuum of care, from primary therapy to the management of relapsed/refractory disease (post-ASCT), as well as in the setting of minimal residual disease eradication. Hear our expert panel as they highlight these improvements and discuss the integration of approved and emerging novel therapies in MM.
This activity can be accessed using the following URL:
- Medical Oncologists
- BMT Specialists
- BMT Nurse Specialists
- Other Clinitions involved in the management of multiple myeloma
•List current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in various multiple myeloma treatment settings
•Describe efficacy and safety data surrounding novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new targeted agent classes in the management of ASCT-eligible patients with multiple myeloma
•Develop regimens with novel components for ASCT-eligible patients with multiple myeloma, including as induction/consolidation or maintenance therapy, or in the setting of early relapse or refractory myeloma
This activity is supported through educational grants from Adaptive Biotechnologies, Bristol Myers Squibb, Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics, Oncopeptides, Inc., and Takeda Oncology.
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Robert Z. Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Director, Myeloma Section, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Robert Z. Orlowski, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; Bristol Myers Squibb; Celgene Corporation; EcoR1 Capital LLC; Forma Therapeutics; Genzyme; GlaxoSmithKline Biologicals; Ionis Pharmaceuticals, Inc.; Janssen Biotech, Inc.; Juno Therapeutics, Inc.; Kite Pharma; Legend Biotech; Molecular Partners; Regeneron Pharmaceuticals, Inc.; Sanofi; Servier Laboratories; STATinMED, Research; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from BioTheryX, Inc.; CARsgen Therapeutics; Celgene Corporation; Exelixis, Inc.; Janssen Biotech, Inc.; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
Other Financial or Material Support Founder of Asylia Therapeutics, Inc., with associated patents and an equity interest, and Director, Scientific Advisory Board.
Nina Shah, MD
Professor of Clinical Medicine
Department of Medicine
The University of California San Francisco
San Francisco, California
Nina Shah, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; Bristol Myers Squibb; CareDx; Indapta Therapeutics, Inc.; GlaxoSmithKline; Karyopharm Therapeutics; Kite Pharma; and Sanofi.
Grant/Research Support from Bristol Myers Squibb/Celgene Corporation; bluebird bio, Inc.; Janssen Pharmaceuticals, Inc.; Nektar Therapeutics; Poseida Therapeutics; Sutro Biopharma, Inc. and TeneoBio, Inc.
Anita D’Souza, MD
Anita D’Souza, MD, has no financial interests/relationships or affiliations in relation to this activity.
PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.
The Medical College of Wisconsin is accredited by the Accreditation Council for continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is co-provided with our educational partner, PVI, PeerView Institute for Medical Education.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.